Clinical Edge Journal Scan

Soy isoflavones improve migraine characteristics and CGRP levels in women with migraine


Key clinical point: Soy isoflavones significantly reduced the frequency and duration of migraine attacks, clinical indices, and calcitonin gene -related peptide (CGRP) levels and improved the quality of life in women with migraine.

Major finding: At 8 weeks, soy isoflavones vs placebo significantly reduced migraine frequency (mean change [MC] 2.36 vs 0.43; P < .001) and duration of attacks (MC 2.50 vs 0.02; P < .001), Migraine Headache Index score (MC 10.46 vs 1.47; P < .001), and CGRP levels (MC 12.18 vs 8.62 ng/L; P = .002) and significantly improved migraine-specific quality-of-life score (MC 16.76 vs 2.52; P < .001). No adverse effects were reported.

Study details: Findings are from a phase 3 trial including 88 adult women with migraine who had not reached menopausal/perimenopausal age and were randomly assigned to receive 50 mg/day soy isoflavones or placebo supplementation for 8 weeks.

Disclosures: This study was supported by Isfahan University of Medical Sciences, Iran . The authors declared no conflicts of interest.

Source: Babapour M et al. Effect of soy isoflavones supplementation on migraine characteristics, mental status and calcitonin gene-related peptide (CGRP) levels in women with migraine: results of randomised controlled trial. Nutr J. 2022;21:50 (Jul 30). Doi: 10.1186/s12937-022-00802-z

Recommended Reading

Commentary: Comparing Migraine Treatments, August 2022
Migraine ICYMI
Galcanezumab effective and safe in episodic migraine
Migraine ICYMI
Galcanezumab reduces total pain burden in treatment-resistant migraine
Migraine ICYMI
Bariatric surgery improves symptoms, quality of life in chronic migraine
Migraine ICYMI
Diabetic retinopathy and migraine prevalence and incidence: What is the link?
Migraine ICYMI